Endeavor

Moffitt Patient Is First To Receive Second CAR T Therapy for Ovarian Cancer

Patient receives second dose of CAR-T immunotherapy for ovarian cancer with special approval from the FDA.

Newly Approved CAR T-Cell Therapy Gives Acute Lymphoblastic Leukemia a New Personalized Option

Novel design and tumor-guided dosing may reduce side effects while maintaining encouraging efficacy

Newly Approved Cell Therapy Afami-Cel Shows Long-Term Tumor Control in Synovial Sarcoma

Phase 2 clinical trial data suggests the engineered T cells can stay active in the body for more than three years

New Immunotherapy Combination Shows Promise in Advanced Lung Cancer

Adding pembrolizumab to TIL therapy shrunk tumors in almost half of trial patients

Moffitt Experts Share Discoveries Driving Innovation in Cancer Immunotherapy

The Society for Immunotherapy of Cancer brings together industry leaders to highlight new research and clinical applications in immunotherapy

Moffitt Hosts Inaugural Cell Coast Conference to Spotlight Breakthroughs in Cellular Immunotherapy

Experts discuss the latest advances in CAR T, TIL and TCR therapies

Experimental Vaccine Gives Young Mother a Shot at Cure

A dendritic cell vaccine changes young mother’s prognosis and landscape for breast cancer treatments

Triplet Therapy Shows Promise in Advanced Lung Cancer

EVOKE-02 study marks an innovative and unconventional approach

FDA Approves New Gene Therapy for Rare Soft Tissue Cancer

First-of-its-kind treatment offers new hope for adults with advanced synovial sarcoma